HC Wainwright Reaffirms Buy Rating for Pyxis Oncology (NASDAQ:PYXS)

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 389.51% from the stock’s current price. HC Wainwright also issued estimates for Pyxis Oncology’s FY2029 earnings at $0.27 EPS.

PYXS has been the topic of a number of other reports. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Stephens increased their price target on Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Finally, Royal Bank Of Canada dropped their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $7.00.

Pyxis Oncology Price Performance

PYXS stock opened at $1.43 on Tuesday. The firm has a market cap of $89.85 million, a PE ratio of -1.11 and a beta of 1.45. Pyxis Oncology has a 12 month low of $0.83 and a 12 month high of $5.55. The firm has a 50 day simple moving average of $1.51 and a 200 day simple moving average of $2.50.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter. As a group, sell-side analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Trading of Pyxis Oncology

Several large investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP purchased a new position in shares of Pyxis Oncology during the fourth quarter valued at $26,000. Barclays PLC lifted its stake in Pyxis Oncology by 1,939.3% in the 4th quarter. Barclays PLC now owns 60,385 shares of the company’s stock worth $69,000 after acquiring an additional 57,424 shares in the last quarter. HRT Financial LP lifted its stake in Pyxis Oncology by 157.5% in the 4th quarter. HRT Financial LP now owns 39,649 shares of the company’s stock worth $45,000 after acquiring an additional 24,251 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Pyxis Oncology by 37.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock worth $58,000 after acquiring an additional 13,550 shares during the period. Finally, Fox Run Management L.L.C. purchased a new position in Pyxis Oncology during the 4th quarter valued at about $26,000. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology News Roundup

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright raised its FY2029 EPS forecast for PYXS (from $0.21 to $0.27), reaffirmed a “Buy” rating and maintains a $7.00 price target — a strong institutional endorsement that can attract buyers and support the rally. HC Wainwright note via MarketBeat
• Neutral Sentiment: Stifel Nicolaus kept a “Buy” rating but lowered its price target from $9.00 to $8.00 — still a large upside versus current levels, but the downgrade in target is a mild headwind for further upside momentum. Benzinga
• Neutral Sentiment: Short-interest reports show effectively 0 shares short with inconsistent/NaN changes reported across data points — the published figures appear unreliable or immaterial, so short-covering is unlikely to be a driver in the near term. (Multiple short-interest entries aggregated.)
• Negative Sentiment: Director Rachel Humphrey executed multiple sales in April (notably 13,896 shares on Apr 21 at an average $1.03, plus earlier small sales on Apr 14 and Apr 17), reducing her holdings — insider selling can signal liquidity needs or waning conviction and may weigh on sentiment. SEC filing: Form 4

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.